Trial Profile
Phase II Study of Azacitidine and Entinostat (SNDX-275) in Patients With Advanced Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Entinostat (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- 01 Mar 2019 Status changed from completed to active, no longer recruiting.
- 03 Jun 2014 Status changed from active, no longer recruiting to completed, as per results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 03 Jun 2014 Partial results (in hormone resistant patient cohort) presented at the 50th Annual Meeting of the American Society of Clinical Oncology.